Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients

Sophie A. Kurk, Petra H. Peeters, Bram Dorresteijn, Pim A. de Jong, Marion Jourdan, Hugo J. Kuijf, Cornelis J.a. Punt, Miriam Koopman, Anne M. MayJournal of Cachexia Sarcopenia and Muscle 2018 · DOI

TL;DR

This study tracked skeletal muscle mass (SMM) in metastatic colorectal cancer patients undergoing various palliative treatments. It reveals that SMM loss, often seen during intensive chemotherapy, is surprisingly reversible and can even be regained during less intensive maintenance or observation periods, suggesting treatment intensity is a key factor.

What Problem Does This Paper Address?

Metastatic colorectal cancer (mCRC) patients often experience a decline in skeletal muscle mass (SMM), a condition known as sarcopenia. This muscle loss is linked to increased chemotherapy toxicity, poorer quality of life, and reduced survival. While the prognostic significance of sarcopenia is established, the dynamic changes in SMM throughout different palliative treatment regimens, including periods of maintenance or observation, have been poorly understood. Clinicians need to know how SMM evolves over time and whether these changes are predictable or reversible to better manage patients and potentially develop new therapeutic interventions.

Methods

The researchers analyzed computed tomography (CT) scans from 450 patients participating in the randomized CAIRO3 study. These scans were collected at four key time points: before the start of initial treatment, at randomization to maintenance therapy or observation, at first disease progression (PD1), and at second disease progression (PD2). Skeletal muscle area was quantified using the Slice-o-matic software, and whole-body SMM was calculated using established formulas. A linear mixed-effects model was employed to assess SMM changes over time, accounting for various factors and treatment arms. The study also looked at body weight and BMI changes, and specifically analyzed subgroups of sarcopenic and non-sarcopenic patients.

Datasets

The study utilized data from the Dutch Colorectal Cancer Group CAIRO3 study, a randomized phase 3 trial. This dataset comprised 1355 CT scans from 450 patients, collected at four distinct time points throughout their palliative treatment. No new datasets were introduced.

Key Insights and Ideas

  • Muscle Loss is Reversible: A major finding is that skeletal muscle mass loss, which occurs during intensive treatments like CAPOX-B, can be regained during less intensive periods, such as maintenance therapy (CAP-B) or observation. This challenges the notion of SMM loss being an irreversible process in this patient population.
  • Treatment Intensity Matters: The study strongly suggests that the intensity of systemic treatment is a significant driver of SMM changes. More aggressive regimens (like initial CAPOX-B or reintroduction treatment) are associated with muscle loss, while less intensive approaches allow for recovery.
  • Body Weight is a Poor Indicator: Changes in body weight and BMI do not accurately reflect SMM changes. Patients can gain weight while losing muscle, making these standard measures insufficient for assessing body composition status in mCRC patients.
  • Sarcopenic Patients Can Still Gain Muscle: Even patients who are already sarcopenic at the start of treatment show patterns of muscle gain during less intensive phases, indicating that interventions to improve SMM might be effective even in this group.

Key Results

  • During the initial 6 cycles of CAPOX-B treatment, SMM significantly decreased by an average of 0.69 kg in the total group.
  • Following initial treatment, SMM recovered during maintenance (CAP-B) or observation periods, increasing by an average of 1.26 kg.
  • Upon reintroduction of more intensive treatment after first progression, SMM again decreased significantly by an average of 2.34 kg.
  • Overall, from the start of initial treatment to the end of reintroduction treatment, there was a net decrease in SMM of 1.79 kg.
  • In contrast, body weight showed less dramatic changes, with a slight average increase of 0.61 kg over the entire follow-up period, despite the overall SMM loss.
  • For sarcopenic patients, initial treatment did not lead to significant SMM change, unlike non-sarcopenic patients who lost muscle.

Limitations and Future Work

The authors acknowledge several limitations:

  • Missing Data: The study relied on a mixed-effects model to handle missing data, but patients who died or discontinued treatment before PD1 or PD2 could not be fully incorporated, potentially introducing selection bias.
  • Exclusion of Certain Patients: The CAIRO3 trial excluded patients with unacceptable toxicity or progression during initial treatment, meaning a particularly poor prognostic group was not represented.
  • 2D CT Analysis: The use of single-slice CT scans for SMM quantification, while practical, can introduce measurement errors due to patient positioning variations. A 3D analysis would offer greater accuracy.
  • No Fat Measurement: Due to the limitations of 2D analysis, fat tissue measurements were not included.
  • Sarcopenia Definitions: There is no universal consensus on sarcopenia cut-off points, complicating cross-study comparisons and generalizability to different ethnicities.

Future work suggested includes investigating interventions like nutritional support and exercise programs, particularly multimodal approaches, to counteract SMM loss during intensive treatments and promote SMM gain. Further research is also needed to understand the prognostic implications of these dynamic SMM changes and to develop targeted therapeutic strategies.

Summary updated

Abstract

This longitudinal study provides a unique insight in SMM changes in mCRC patients during palliative systemic treatment regimens, including observation. Our data show that muscle loss is reversible and may be influenced by the intensity of systemic regimens. Although studies have shown prognostic capacity for SMM, the effects of subsequent changes in SMM are unknown and may be clues for new future therapeutic interventions.
BibTeX
@article{kurk2018impact,
  author = {Sophie A. Kurk and Petra H. Peeters and Bram Dorresteijn and Pim A. de Jong and Marion Jourdan and Hugo J. Kuijf and Cornelis J.A. Punt and Miriam Koopman and Anne M. May},
  title = {{Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients}},
  journal = {Journal of Cachexia Sarcopenia and Muscle},
  year = {2018},
  doi = {10.1002/jcsm.12337},
}
Figure